Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology

Vaccine

Volumn 25, Issue 29, 2007, Pages 5378-5389

  Cyr, Sonya L ^a,b   Jones, Taff ^b   Stoica Popescu, Ioana ^b   Brewer, Angela ^a   Chabot, Sophie ^c   Lussier, Michelle ^b   Burt, David ^b   Ward, Brian J ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b GLAXOSMITHKLINE   (Canada)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Intranasal immunization; Proteosomes; Protollin; RSV; Vaccine

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OUTER MEMBRANE PROTEIN; PROTEASOME; PROTOLLIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; EOSINOPHILIA; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; CD8-POSITIVE T-LYMPHOCYTES; CYSTEINE ENDOPEPTIDASES; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; EOSINOPHILIA; FEMALE; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; LUNG; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PROTEASOME ENDOPEPTIDASE COMPLEX; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; T-LYMPHOCYTE SUBSETS; VACCINES, SUBUNIT; VIRAL PROTEINS;

EID: 34347243513     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.004     Document Type: Article

References (57)

1. Lindemans C.A., Coffer P.J., Schellens I.M., de Graaff P.M., Kimpen J.L., and Koenderman L. Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism. J Immunol 176 9 (2006) 5529-5537
2. Piedimonte G. Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link. Respir Res 3 Suppl. 1 (2002) S21-S25
3. Rutigliano J.A., and Graham B.S. Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol 173 5 (2004) 3408-3417
4. Tortorolo L., Langer A., Polidori G., Vento G., Stampachiacchere B., Aloe L., et al. Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection. Am J Respir Crit Care Med 172 2 (2005) 233-237
5. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., and Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89 4 (1969) 405-421
6. Prince G.A., Curtis S.J., Yim K.C., and Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82 Pt. 12 (2001) 2881-2888
7. Boelen A., Andeweg A., Kwakkel J., Lokhorst W., Bestebroer T., Dormans J., et al. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 19 7-8 (2000) 982-991
8. Johnson T.R., Teng M.N., Collins P.L., and Graham B.S. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol 78 11 (2004) 6024-6032
9. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., and Anderson L.J. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70 5 (1996) 2852-2860
10. Puthothu B., Krueger M., Forster J., and Heinzmann A. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J Infect Dis 193 3 (2006) 438-441
11. Walzl G., Matthews S., Kendall S., Gutierrez-Ramos J.C., Coyle A.J., Openshaw P.J., et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med 193 7 (2001) 785-792
12. Haynes L.M., Jones L.P., Barskey A., Anderson L.J., and Tripp R.A. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol 77 18 (2003) 9831-9844
13. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 82 5 (2004) 497-505
14. Petrovsky N., and Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82 5 (2004) 488-496
15. Moghaddam A., Olszewska W., Wang B., Tregoning J.S., Helson R., Sattentau Q.J., et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12 8 (2006) 905-907
16. Scott P.D., Ochola R., Ngama M., Okiro E.A., James Nokes D., Medley G.F., et al. Molecular analysis of respiratory syncytial virus reinfections in infants from coastal Kenya. J Infect Dis 193 1 (2006) 59-67
17. Hall C.B., Walsh E.E., Long C.E., and Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163 4 (1991) 693-698
18. Hancock G.E., Heers K.M., Pryharski K.S., Smith J.D., and Tiberio L. Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine 21 27-30 (2003) 4348-4358
19. Cyr S. Mucosal immunology. 11th International Congress. IDrugs 5 8 (2002) 753-756
20. Bruder D., Srikiatkhachorn A., and Enelow R.I. Cellular immunity and lung injury in respiratory virus infection. Viral Immunol 19 2 (2006) 147-155
21. Goetsch L., Gonzalez A., Plotnicky-Gilquin H., Haeuw J.F., Aubry J.P., Beck A., et al. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect Immunol 69 10 (2001) 6434-6444
22. Tebbey P.W., Unczur C.A., LaPierre N.A., and Hancock G.E. A novel and effective intranasal immunization strategy for respiratory syncytial virus. Viral Immunol 12 1 (1999) 41-45
23. Bastien N., Trudel M., and Simard C. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 17 7-8 (1999) 832-836
24. Langley J.M., Halperin S.A., McNeil S., Smith B., Jones T., Burt D., et al. Safety and immunogenicity of a Proteosometrade mark-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine (2005)
25. Jones T., Allard F., Cyr S.L., Tran S.P., Plante M., Gauthier J., et al. A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine 21 25-26 (2003) 3706-3712
26. Plante M., Jones T., Allard F., Torossian K., Gauthier J., St-Felix N., et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine 20 1-2 (2001) 218-225
27. Chabot S., Brewer A., Lowell G., Plante M., Cyr S., Burt D.S., et al. A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 23 11 (2005) 1374-1383
28. Fries L.F., Montemarano A.D., Mallett C.P., Taylor D.N., Hale T.L., and Lowell G.H. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immunol 69 7 (2001) 4545-4553
29. Jones T., Adamovicz J.J., Cyr S.L., Bolt C.R., Bellerose N., Pitt L.M., et al. Intranasal Protollintrade mark/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine (2005)
30. Lowell G.H. Proteosomes for improved nasal, oral, or injectable vaccines. In: Levine M.M., Woodrow G.C., Kaper J.B., and Cobon G.S. (Eds). New generation vaccines. 2nd ed. (1997), Marcel Dekker, Inc., New York 193-206
31. Jones T., Cyr S., Allard F., Bellerose N., Lowell G.H., and Burt D.S. Protollin: a novel adjuvant for intranasal vaccines. Vaccine 22 27-28 (2004) 3691-3697
32. Etchart N., Baaten B., Andersen S.R., Hyland L., Wong S.Y., and Hou S. Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. Eur J Immunol 36 5 (2006) 1136-1144
33. Payment P., and Trudel M. Isolation and identification of viruses. Methods and techniques in virology (1993), Marccel Dekker, Inc., New York
34. Roder C., Krusat T., Reimers K., and Werchau H. Purification of respiratory syncytial virus F and G proteins. J Chromatogr B Biomed Sci Appl 737 1-2 (2000) 97-106
35. Jones D.H., McBride B.W., Roff M.A., Maloney V., and Farrar G.H. Purification and characterization of simian immunodeficiency virus (SIVmac) envelope glycoprotein gp130 from virus-infected cells. Vaccine 12 3 (1994) 250-258
36. Johnstone C., de L.P., Medina F., Melero J.A., Garcia-Barreno B., and Del V.M. Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the long strain of respiratory syncytial virus. J Gen Virol 85 Pt. 11 (2004) 3229-3238
37. + T cell responses. J Immunol 165 11 (2000) 6487-6495
38. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse III H.C., and Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68 8 (1994) 5321-5325
39. Matthews S.P., Tregoning J.S., Coyle A.J., Hussell T., and Openshaw P.J. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol 79 4 (2005) 2050-2057
40. Zughaier S.M., Zimmer S.M., Datta A., Carlson R.W., and Stephens D.S. Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect Immunol 73 5 (2005) 2940-2950
41. Hoebe K., Janssen E.M., Kim S.O., Alexopoulou L., Flavell R.A., Han J., et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol 4 12 (2003) 1223-1229
42. Haynes L.M., Moore D.D., Kurt-Jones E.A., Finberg R.W., Anderson L.J., and Tripp R.A. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 75 22 (2001) 10730-10737
43. Haeberle H.A., Takizawa R., Casola A., Brasier A.R., Dieterich H.J., Van Rooijen N., et al. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis 186 9 (2002) 1199-1206
44. Monick M.M., Yarovinsky T.O., Powers L.S., Butler N.S., Carter A.B., Gudmundsson G., et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 278 52 (2003) 53035-53044
45. Datta S.K., Redecke V., Prilliman K.R., Takabayashi K., Corr M., Tallant T., et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 170 8 (2003) 4102-4110
46. Rock K.L. The ins and outs of cross-presentation. Nat Immunol 4 10 (2003) 941-943
47. Peebles Jr. R.S., Sheller J.R., Collins R.D., Jarzecka K., Mitchell D.B., and Graham B.S. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J Infect Dis 182 3 (2000) 671-677
48. Brayden D.J., and Baird A.W. Microparticle vaccine approaches to stimulate mucosal immunisation. Microbes Infect 3 10 (2001) 867-876
49. Frey A., and Neutra M.R. Targeting of mucosal vaccines to Peyer's patch M cells. Behring Inst Mitt 98 (1997) 376-389
50. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 2 (2006) 148-158
51. Taylor G., Stott E.J., Hughes M., and Collins A.P. Respiratory syncytial virus infection in mice. Infect Immunol 43 2 (1984) 649-655
52. Englund J.A. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. Pediatr Infect Dis J 13 5 (1994) 449-453
53. + cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection. J Virol 78 6 (2004) 3014-3023
54. McCarthy A.J., Kingman H.M., Kelly C., Taylor G.S., Caul E.O., Grier D., et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 24 12 (1999) 1315-1322
55. Curtis J.L. Cell-mediated adaptive immune defense of the lungs. Proc Am Thorac Soc 2 5 (2005) 412-416
56. Richter B.W., Onuska J.M., Niewiesk S., Prince G.A., and Eichelberger M.C. Antigen-dependent proliferation and cytokine induction in respiratory syncytial virus-infected cotton rats reflect the presence of effector-memory T cells. Virology 337 1 (2005) 102-110
57. Woodland D.L., Hogan R.J., and Zhong W. Cellular immunity and memory to respiratory virus infections. Immunol Res 24 1 (2001) 53-67